Recent recommendations from the American College of Cardiology (ACC), American College of Clinical Pharmacy (ACCP), and European Society of Cardiology (ESC) suggest that all patients suffering from heart failure should be administered medications that inhibit SGLT2. Here, SLC5A2 is linked to heart failure.